136 related articles for article (PubMed ID: 35466060)
1. Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy.
Otsuka H; Uemura K; Kondo N; Sumiyoshi T; Okada K; Seo S; Murakami Y; Takahashi S
Pancreatology; 2022 Jun; 22(5):583-589. PubMed ID: 35466060
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of intraoperative peritoneal washing cytology for patients with potentially resectable pancreatic ductal adenocarcinoma.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Hoshi N; Hoshi S; Hirabayashi K; Ogata Y
Pancreatology; 2017; 17(1):109-114. PubMed ID: 27840175
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status.
Sakoda T; Uemura K; Kondo N; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
J Gastrointest Surg; 2021 Nov; 25(11):2871-2880. PubMed ID: 33768425
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytology.
Fukasawa M; Watanabe T; Tanaka H; Itoh A; Kimura N; Shibuya K; Yoshioka I; Murotani K; Hirabayashi K; Fujii T
J Hepatobiliary Pancreat Sci; 2023 Nov; 30(11):1261-1272. PubMed ID: 37750024
[TBL] [Abstract][Full Text] [Related]
5. Increased incidence of positive peritoneal lavage cytology early after fine needle aspiration in patients with pancreatic ducal adenocarcinoma.
Sakamoto T; Onda S; Shirai Y; Tsunematsu M; Okui N; Gocho T; Ikegami T
Pancreatology; 2023 Mar; 23(2):201-203. PubMed ID: 36702676
[TBL] [Abstract][Full Text] [Related]
6. Predictive impacts of peritoneal washing cytology for surgical resection-intended pancreatic cancer cases: Establishment of planned staging laparoscopy criteria.
Tanaka N; Takami H; Hayashi M; Inokawa Y; Kurimoto K; Hattori N; Kanda M; Tanaka C; Nakayama G; Kodera Y
J Hepatobiliary Pancreat Sci; 2023 Nov; 30(11):1273-1281. PubMed ID: 37799038
[TBL] [Abstract][Full Text] [Related]
7. Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients.
Gudmundsdottir H; Yonkus JA; Alva-Ruiz R; Kendrick ML; Smoot RL; Warner SG; Starlinger P; Thiels CA; Nagorney DM; Cleary SP; Grotz TE; Truty MJ
J Am Coll Surg; 2023 Jul; 237(1):49-57. PubMed ID: 37026837
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.
Murakawa M; Kawahara S; Takahashi D; Kamioka Y; Yamamoto N; Kobayashi S; Ueno M; Morimoto M; Sawazaki S; Tamagawa H; Ohshima T; Yukawa N; Rino Y; Morinaga S
World J Surg Oncol; 2023 Aug; 21(1):263. PubMed ID: 37620940
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of high-quality testing for peritoneal lavage cytology in pancreatic cancer.
Tanemura M; Furukawa K; Mikamori M; Asaoka T; Yasuoka H; Marukawa D; Urata Y; Yamada D; Kobayashi S; Eguchi H
Sci Rep; 2024 May; 14(1):10199. PubMed ID: 38702437
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma.
Suenaga M; Fujii T; Yamada S; Hayashi M; Shinjo K; Takami H; Niwa Y; Sonohara F; Shimizu D; Kanda M; Kobayashi D; Tanaka C; Nakayama G; Koike M; Fujiwara M; Kondo Y; Kodera Y
Ann Surg Oncol; 2021 Apr; 28(4):2277-2286. PubMed ID: 32875467
[TBL] [Abstract][Full Text] [Related]
11. Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective.
Kurata Y; Shiraki T; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2021 Mar; 19(1):85. PubMed ID: 33752677
[TBL] [Abstract][Full Text] [Related]
12. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma.
Kawahara K; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
Clin Exp Metastasis; 2022 Apr; 39(2):311-322. PubMed ID: 35000025
[TBL] [Abstract][Full Text] [Related]
13. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
16. Extracellular volume fraction determined by dual-layer spectral detector CT: Possible role in predicting the efficacy of preoperative neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Fujita N; Ushijima Y; Itoyama M; Okamoto D; Ishimatsu K; Wada N; Takao S; Murayama R; Fujimori N; Nakata K; Nakamura M; Yamamoto T; Oda Y; Ishigami K
Eur J Radiol; 2023 May; 162():110756. PubMed ID: 36907069
[TBL] [Abstract][Full Text] [Related]
17. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery.
Ariake K; Mizuma M; Motoi F; Maeda S; Morikawa T; Ishida M; Ohtsuka H; Aoki S; Miura T; Takadate T; Nakagawa K; Kamei T; Unno M
Ann Surg Oncol; 2021 Oct; 28(11):6246-6254. PubMed ID: 33611747
[TBL] [Abstract][Full Text] [Related]
18. Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytology.
Ohgi K; Sugiura T; Okamura Y; Ashida R; Yamada M; Otsuka S; Todaka A; Uesaka K
Langenbecks Arch Surg; 2023 Apr; 408(1):165. PubMed ID: 37103587
[TBL] [Abstract][Full Text] [Related]
19. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection.
Satoi S; Murakami Y; Motoi F; Uemura K; Kawai M; Kurata M; Sho M; Matsumoto I; Yanagimoto H; Yamamoto T; Mizuma M; Unno M; Hashimoto Y; Hirono S; Yamaue H; Honda G; Nagai M; Nakajima Y; Shinzeki M; Fukumoto T; Kwon AH
J Gastrointest Surg; 2015 Jan; 19(1):6-14; discussion 14. PubMed ID: 25316482
[TBL] [Abstract][Full Text] [Related]
20. Oncologic impact of preoperative prognostic nutritional index change in resected pancreatic cancer following neoadjuvant chemotherapy.
Kim KH; Hwang HK; Kang IC; Lee WJ; Kang CM
Pancreatology; 2020 Mar; 20(2):247-253. PubMed ID: 31889624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
